{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:06:48Z","timestamp":1790255208323,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"National League Against Cancer","doi-asserted-by":"publisher","award":["EL2022.LNCC\/NaL"],"award-info":[{"award-number":["EL2022.LNCC\/NaL"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201294","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:33:29Z","timestamp":1784302409000},"page":"201294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["TAP1 deficiency reshapes tumor antigenicity and enables CD8 T cell targeting in colorectal cancer"],"prefix":"10.1016","volume":"34","author":[{"given":"Audrey","family":"Merienne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0324-2335","authenticated-orcid":false,"given":"Kathleen","family":"Ducoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Deleine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Deiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Machu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0002-729X","authenticated-orcid":false,"given":"Edouard","family":"Leveque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Oger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Duchalais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fourquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bossard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1407-6546","authenticated-orcid":false,"given":"Nathalie","family":"Labarri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8386-2025","authenticated-orcid":false,"given":"Houssem","family":"Benlalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Jarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0092-3919","authenticated-orcid":false,"given":"Nadine","family":"Gervois-Segain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201294_bib1","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1186\/s12885-025-15138-0","article-title":"Global burden of colorectal cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN","volume":"25","author":"Wu","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omton.2026.201294_bib2","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201294_bib3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201294_bib4","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201294_bib5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/1078-0432.CCR-18-1851","article-title":"The Immunoscore: Colon Cancer and Beyond","volume":"26","author":"Angell","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201294_bib6","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/bjs.11204","article-title":"Mechanisms of immunogenicity in colorectal cancer","volume":"106","author":"Sillo","year":"2019","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.omton.2026.201294_bib7","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201294_bib8","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/jnci\/djz093","article-title":"Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches","volume":"111","author":"Franke","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.omton.2026.201294_bib9","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41591-023-02497-z","article-title":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial","volume":"29","author":"Thibaudin","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201294_bib10","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.7150\/ijbs.64077","article-title":"Immunotherapy in colorectal cancer: current achievements and future perspective","volume":"17","author":"Fan","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.omton.2026.201294_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201294_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: an overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201294_bib13","doi-asserted-by":"crossref","first-page":"a006957","DOI":"10.1101\/cshperspect.a006957","article-title":"T-Cell Tolerance: Central and Peripheral","volume":"4","author":"Xing","year":"2012","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.omton.2026.201294_bib14","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1158\/2326-6066.CIR-15-0134","article-title":"Neoepitopes of Cancers: Looking Back, Looking Ahead","volume":"3","author":"Srivastava","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2026.201294_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201294_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184782","article-title":"More T cell receptors to the RAScue in cancer?","volume":"134","author":"Tran","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201294_bib17","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/jnci\/djt184","article-title":"MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells","volume":"105","author":"Leone","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.omton.2026.201294_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.coi.2019.12.004","article-title":"To TAP or not to TAP: alternative peptides for immunotherapy of cancer","volume":"64","author":"Marijt","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.omton.2026.201294_bib19","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41423-021-00634-7","article-title":"HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy","volume":"18","author":"Anderson","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omton.2026.201294_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12885-022-10491-w","article-title":"Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy","volume":"23","author":"Tu","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omton.2026.201294_bib21","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1038\/s41467-025-60281-8","article-title":"TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I\/II dose-escalation study","volume":"16","author":"Emmers","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201294_bib22","first-page":"741","volume":"348","author":"Trowsdale","year":"1990"},{"key":"10.1016\/j.omton.2026.201294_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13073-018-0598-2","article-title":"Acquired mechanisms of immune escape in cancer following immunotherapy","volume":"10","author":"Iorgulescu","year":"2018","journal-title":"Genome Med."},{"key":"10.1016\/j.omton.2026.201294_bib24","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1084\/jem.20180577","article-title":"Identification of non-mutated neoantigens presented by TAP-deficient tumors","volume":"215","author":"Marijt","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201294_bib25","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.humpath.2010.05.014","article-title":"Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer","volume":"41","author":"Kasajima","year":"2010","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.omton.2026.201294_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356143","article-title":"TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer","volume":"6","author":"Ling","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2026.201294_bib27","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1158\/0008-5472.CAN-05-0044","article-title":"Immunoselective Pressure and Human Leukocyte Antigen Class I Antigen Machinery Defects in Microsatellite Unstable Colorectal Cancers","volume":"65","author":"Kloor","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201294_bib28","first-page":"88","article-title":"Expression of transporters associated with antigen processing and human leucocyte antigen class I in malignant melanoma and its association with prognostic factors","volume":"158","author":"Tao","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.omton.2026.201294_bib29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00262-009-0769-5","article-title":"Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer","volume":"59","author":"Seliger","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201294_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3892\/mco.2013.194","article-title":"Downregulation of expression of transporters associated with antigen processing 1 and 2 and human leukocyte antigen I and its effect on immunity in nasopharyngeal carcinoma patients","volume":"2","author":"Ren","year":"2014","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201294_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187323","article-title":"Downregulation of TAP1 and TAP2 in early stage breast cancer","volume":"12","author":"Henle","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2026.201294_bib32","article-title":"Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common HLA-B and TAP transcriptional silencing across advanced pediatric solid cancers","volume":"14","author":"Lim","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201294_bib33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12943-025-02276-z","article-title":"IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer","volume":"24","author":"Ranjan","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omton.2026.201294_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nm1381","article-title":"Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants","volume":"12","author":"Van Hall","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201294_bib35","doi-asserted-by":"crossref","first-page":"10119","DOI":"10.1073\/pnas.0802753105","article-title":"Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway","volume":"105","author":"Hage","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.omton.2026.201294_bib36","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.4049\/jimmunol.1102060","article-title":"Different Expression Levels of the TAP Peptide Transporter Lead to Recognition of Different Antigenic Peptides by Tumor-Specific CTL","volume":"187","author":"Durgeau","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201294_bib37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00262-021-02984-7","article-title":"Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement","volume":"71","author":"Marijt","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201294_bib38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molimm.2015.04.014","article-title":"Proteolytic enzymes involved in MHC class I antigen processing: A guerrilla army that partners with the proteasome","volume":"68","author":"L\u00e1zaro","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omton.2026.201294_bib39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.molimm.2014.06.006","article-title":"Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire","volume":"62","author":"Oliveira","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omton.2026.201294_bib40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.molimm.2018.03.029","article-title":"TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class Ilow cancers","volume":"113","author":"Marijt","year":"2019","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omton.2026.201294_bib41","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1562834","article-title":"The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status","volume":"8","author":"Ott","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2026.201294_bib42","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41379-019-0322-9","article-title":"The inhibitory receptor CD94\/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE\/\u03b22m overexpression","volume":"33","author":"Eug\u00e8ne","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.omton.2026.201294_bib43","first-page":"1459","article-title":"High Avidity Melanoma-reactive Cytotoxic T Lymphocytes Are Efficiently Induced from Peripheral Blood Lymphocytes on Stimulation by Peptide-pulsed Melanoma Cells","volume":"6","author":"Gervois","year":"2000","journal-title":"Clin. Cancer Res."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:38:06Z","timestamp":1790253486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001700"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201294","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TAP1 deficiency reshapes tumor antigenicity and enables CD8 T cell targeting in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201294"}}